Immunobiology of IL-37: mechanism of action and clinical perspectives

References

• Dinarello CA, Arend W, Sims J, et al. IL-1 family nomenclature. Nat Immunol 2010;11(11):973
   PubMed Web of Science ®Google Scholar
• Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010;11(11):1014-24
   PubMed Web of Science ®Google Scholar
• Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011;22(3):127-47
   PubMed Web of Science ®Google Scholar
• Luo Y, Cai X, Wang S, et al. IL-37 suppresses contact hypersensitivity by inducing tolerogenic dendritic cells. Cytokine 2013;63:283
   Web of Science ®Google Scholar
• Dinarello CA, Bufler P. Interleukin-37. Semin Immunol 2013;25(6):466-8
   PubMed Web of Science ®Google Scholar
• Kumar S, Hannin CR, Brigham-Burke MR, et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 2002;18(2):61-71
   PubMed Web of Science ®Google Scholar
• Bufler P, Azam T, Gamboni-Robertson F, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci USA 2002;99(21):13723-8
   PubMed Web of Science ®Google Scholar
• Nold MF, Nold-Petry CA, Lo C, et al. Interleukin 37 employs the IL-1 family inhibitory receptor SIGIRR and the alpha chain of the IL-18 receptor to suppress innate immunity. Cytokine 2013;63:287
   Web of Science ®Google Scholar
• Bufler P, Gamboni-Robertson F, Azam T, et al. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 2004;381(1):503-10
   PubMedGoogle Scholar
• Sharma S, Kulk N, Nold MF, et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 2008;180(8):5477-82
   PubMed Web of Science ®Google Scholar
• Bulau A-M, Gruschka A, Schwaiger R, et al. Anti-IL-37 antibody abrogates the protection in IL-37 transgenic mice to LPS-induced septic shock. Cytokine 2013;63(3):250
   Web of Science ®Google Scholar
• Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127(3): e1-e70 701-21
   PubMed Web of Science ®Google Scholar
• Teng X, Hu Z, Wei X, et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing pro-inflammatory cytokine production. J Immunol 2014;192(1):1815-23
   PubMedGoogle Scholar
• Harskamp CT, Armstrong AW. Immunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapies. Semin Cutan Med Surg 2013;32(3):132-9
   PubMed Web of Science ®Google Scholar
• McNamee EN, Masterson JC, Jedlicka P, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA 2011;108(40):16711-16
   PubMed Web of Science ®Google Scholar
• Imaeda H, Takahashi K, Fujimoto T, et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 2013;172(3):410-16
   PubMed Web of Science ®Google Scholar
• Song L, Qiu F, Fan Y, et al. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol 2013;33(1):111-17
   PubMed Web of Science ®Google Scholar
• Li C, Zhao P, Xiguang S, et al. Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré Syndrome. Mediat Inflamm 2013;8(1):1-9
   Google Scholar
• Moschen AR, Molnar C, Enrich B, et al. Adipose and liver expression of IL-1 family members in morbid obesity and effects of weight loss. Mol Med 2011;17(7-8):840-5
   PubMed Web of Science ®Google Scholar
• Bulau A-M, Fink M, Maucksch C, et al. In vivo expression of Interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. Sci World J 2011;11(1):2480-90
   Google Scholar
• Sakai N, Van Sweringen HL, Belizaire RM, et al. Interluekin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 2012;27(10):1609-16
   PubMed Web of Science ®Google Scholar
• Li C, Ji HF, Cai YJ, et al. Serum Interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. J Interferon Cytokine Res 2013;33(10):612-18
   PubMed Web of Science ®Google Scholar
• Ji Q, Zeng Q, Huang Y, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediat Inflamm 2014;3(1):1-9
   Google Scholar
• Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J Biol Chem 2000;275(2):1169-75
   PubMed Web of Science ®Google Scholar
• Kumar S, McDonnell PC, Lehrt R, et al. Identification and initial characterization of four novel members of the Interleukin-1 family. J Biol Chem 2000;275(4):10308-14
   PubMedGoogle Scholar
• Busfield SJ, Comrack CA, Yu G, et al. Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 2000;66(1):213-16
   PubMedGoogle Scholar
• Pan G, Risser P, Mao W, et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-Rrp. Cytokine 2001;13(1):1-7
   PubMed Web of Science ®Google Scholar
• Ji Q, Zeng Q, Huang Y, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediat Inflamm 2014;3(1):1-9
   Google Scholar